Key issues in developing infrastructure to support joint working with industry in clinical research

Collaborative partnerships – Lancaster University
September 2012

Dr Louise Wood
R&D Directorate, Department of Health
NIHR Clinical Research Infrastructure

Invention

- Biomedical Research Centres
- Biomedical Research Units
- Experimental Cancer Medicine Centres
- Clinical Research Facilities
- Translational Research Partnerships and Collaborations
- Patient Safety Translational Research Centres

Evaluation

- Healthcare Technology Co-operatives
- Diagnostic Evidence Co-operatives
- Collabs for Leadership in Applied Health Research and Care

Adoption

Clinical Research Networks
Total Recruitment and Number of Studies Reporting Recruitment in Cumbria and Lancashire CLRN

These interim totals will be refreshed and confirmed on 26 April 2013

*'to date' = 10 Sep 2012
“I look forward to future partnership and to the pharmaceutical industry continuing to make a significant contribution to health and prosperity of the UK.”

- Tony Blair 2001
Evolving life sciences industry

• Dwindling development pipelines – “broken drug development”
• Blockbuster drug patents expiring – revenues difficult to replace
• Diversification away from reliance on novel drugs
• Consolidation/mergers/rationalisation and narrowing of R&D portfolios/joint ventures
• Outsourcing of R&D – CROs and academia
• Competition and new market opportunities
• Pricing pressures and reimbursement reforms
• Closer working between pharma, biotech, diagnostics and med tech
UK Life sciences ecosystem

Streamlined processes ? Appetite for collaboration ? Incentives ?
Funding ? Reputation ? Skills ?
We have the strengths, but we recognise that too often we have failed to capitalise on them.

This is an ambitious strategy to change that and to finally join up life sciences in the UK:
• to open up universities and business to more collaboration;
• to invest in the best British ideas at an early stage;
• to tear down the regulatory barriers you face;
• and crucially, to open up the NHS to new innovations and new clinical trials.

December 2011
Strategy for UK Life Sciences

INNOVATION HEALTH AND WEALTH
ACCELERATING ADOPTION AND DIFFUSION IN THE NHS

Investing in UK Health and Life Sciences

BIS & DH  NHS CE  Prime Minister
Strategy for UK Life Sciences

1. Building a life sciences ecosystem
   • Making it easier to commercialise academic research
   • Putting clinical research at the heart of innovation in the NHS
   • Encouraging adoption and diffusion of innovation in the NHS
   • Promoting the UK as the place to invest and deliver life sciences innovation

2. Attracting, developing and rewarding the best talent
   • Attracting world-leading talent in areas of strategic priority for the UK
   • Developing scientific excellence alongside commercial rigour

3. Overcoming barriers and creating incentives for the promotion of health care innovation
   • Tax changes to incentivise investment in R&D
   • Funding to incentivise early-stage investment
   • Regulation
Joint Working with Industry

- NHS/University partnerships
- Culture
- Costing and Contracting
- Incentives
- Collaboration/fee-for-service
- Reorganisations
- Publication policy
- New ways of working
- Negotiations conducted at right level